Understand the source comparison
Peptides for Multiple Sclerosis Protocol Evidence Guide: Comparison
Thymalin Thymic regeneration; increases Tregs and reduces autoreactive T-cells 2017 Russian RCT: 42% relapse reduction when added to interferon; improved EDSS scores in 63% vs 31% 10mg IM daily × 10 days, repeated quarterly Single-center study; no double-blind
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic regeneration; increases Tregs and reduces autoreactive T-cells
- 2017 Russian RCT: 42% relapse reduction when added to interferon; improved EDSS scores in 63% vs 31%
- 10mg IM daily × 10 days, repeated quarterly
- Single-center study; no double-blind placebo control; limited to relapsing-remitting MS
- Strongest immune-modulating evidence in MS; adjunctive use plausible
- Cerebrolysin
- Microglial M1→M2 shift; neurotrophic factor delivery; reduces chronic neuroinflammation
- 2008 open-label trial: reduced gadolinium-enhancing lesions; meta-analysis shows cognitive benefit in neurodegeneration
- 10–30mL IV infusion daily × 20 days
- MS-specific data limited; most evidence from stroke/AD populations
- Mechanistically relevant but clinical MS evidence weak
- Dihexa
- HGF receptor agonist; promotes oligodendrocyte maturation and remyelination
- Preclinical only; 7× synaptogenesis increase; 60% cognitive improvement in animal models
- Research doses 1–5mg SC; human MS trials nonexistent
- Zero human MS data; entirely mechanistic rationale
- Promising remyelination target with no clinical validation yet
- P21
- CNTF pathway activator; neuroprotective and anti-apoptotic
- Animal models show axonal preservation; no MS-specific trials
- Research doses 500mcg–1mg SC 2–3× weekly
- Mechanism overlaps with approved drugs (e.g., glatiramer acetate)
- Redundant with existing therapies; unclear added value